Tracking the COVID-19 vaccines: The global landscape

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, necessitated rapid vaccine development.
• Various vaccine platforms, including mRNA, viral vector, and virus-like particles (VLPs), have been employed.
• Understanding the characteristics of these vaccines is crucial for global health strategies.

Purpose of the Study:

• To systematically review and compare the efficacy and safety of different COVID-19 vaccines.
• To provide an overview of vaccine candidates, including mRNA-1273, BNT162b2, AZD1222, Ad26.COV2.S, and NVX-CoV2373.
• To inform public health policies and clinical decision-making regarding COVID-19 vaccination.

Main Methods:

• Systematic literature search using PRISMA guidelines.
• Inclusion of data from clinical trials and real-world evidence.
• Comparative analysis of vaccine efficacy, immunogenicity, and safety profiles.

Main Results:

• mRNA vaccines (e.g., mRNA-1273, BNT162b2) demonstrate high efficacy and robust immune responses.
• Viral vector vaccines (e.g., AZD1222, Ad26.COV2.S) show good protection against severe disease.
• Novavax vaccine (NVX-CoV2373) with Matrix-M™ adjuvant also exhibits promising efficacy and safety.

Conclusions:

• Multiple COVID-19 vaccine platforms offer significant protection against SARS-CoV-2 infection and severe disease.
• Continued surveillance and research are essential to monitor long-term effectiveness and address emerging variants.
• Vaccination remains a cornerstone in managing the COVID-19 pandemic.